How Long Has Semaglutide Been on the Market? A Complete Timeline from FDA Approval to 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide first received FDA approval on December 5, 2017, as Ozempic for type 2 diabetes, making it 8.4 years old as of April 2026
• The weight-loss formulation (Wegovy) was approved June 4, 2021, nearly four years after the diabetes version
• Compounded semaglutide became widely available in mid-2022 during the first major Wegovy shortage and remains legal in 2026 due to ongoing FDA shortage designations
• The oral version (Rybelsus) was approved September 20, 2019, as the first oral GLP-1 receptor agonist

Direct answer (40-60 words)

Semaglutide has been on the U.S. market for 8.4 years as of April 2026. The injectable diabetes formulation (Ozempic) was approved December 5, 2017. The higher-dose weight-loss version (Wegovy) followed on June 4, 2021. Compounded semaglutide became widely available in 2022 during brand-name shortages and remains accessible in 2026.

Table of contents

1. The complete FDA approval timeline: 2017 to 2026
2. What most articles get wrong about semaglutide's "launch date"
3. The three distinct formulations and why approval dates matter
4. The shortage years: how supply problems created the compounded market
5. Clinical trial history: semaglutide existed long before 2017
6. The global timeline: when other countries approved semaglutide
7. Patent expiration and biosimilar timeline through 2032
8. How to determine which version you're actually taking
9. The compounded semaglutide legal window: 2022 to present
10. What the next five years look like for semaglutide availability
11. FAQ
12. Sources

The complete FDA approval timeline: 2017 to 2026

The FDA has approved semaglutide three separate times for three different formulations and indications. Each approval represents a distinct regulatory pathway and clinical trial program.

Date	Brand Name	Formulation	Indication	Starting Dose	Maintenance Dose
December 5, 2017	Ozempic	Injectable (subcutaneous)	Type 2 diabetes	0.25 mg weekly	0.5 mg to 2 mg weekly
September 20, 2019	Rybelsus	Oral tablet	Type 2 diabetes	3 mg daily	7 mg to 14 mg daily
June 4, 2021	Wegovy	Injectable (subcutaneous)	Chronic weight management	0.25 mg weekly	2.4 mg weekly

The 2017 Ozempic approval marked semaglutide's entry to the U.S. market. The molecule itself had been in human clinical trials since 2011, but December 2017 is the first date a patient could receive a prescription filled at a U.S. pharmacy.

The 2019 Rybelsus approval was the first oral GLP-1 receptor agonist approved anywhere in the world. Previous GLP-1 medications (liraglutide, dulaglutide, exenatide) were all injectable. Oral semaglutide required a novel absorption enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to survive gastric acid and cross the intestinal barrier.

The 2021 Wegovy approval represented the same molecule at a higher dose with a different indication. The FDA required separate Phase 3 trials (the STEP program, N = 4,567 across five trials) despite Ozempic already being on the market. The regulatory logic: diabetes and obesity are distinct disease states requiring independent evidence.

What most articles get wrong about semaglutide's "launch date"

Most consumer health articles cite 2021 as semaglutide's launch year because that's when Wegovy (the weight-loss version) was approved and media coverage exploded. This is incorrect.

Semaglutide entered the U.S. market in December 2017. By the time Wegovy launched in June 2021, Ozempic had already been prescribed to more than 2 million U.S. patients for diabetes (Novo Nordisk investor reports, Q2 2021). The molecule had a 3.5-year real-world safety record before the first weight-loss prescription was written.

The confusion stems from conflating "when did semaglutide become famous" with "when did it become available." The former is 2021 to 2022 (driven by social media, celebrity use, and Wegovy's approval). The latter is 2017.

This distinction matters clinically. When a provider evaluates semaglutide's safety profile, the relevant dataset spans 8+ years and includes both diabetes and obesity populations. A medication approved in 2021 would have a much thinner post-market surveillance record.

The second common error: stating that compounded semaglutide is "new" or "experimental." Compounded semaglutide uses the identical active pharmaceutical ingredient that has been FDA-approved since 2017. The compounding process is newer (widespread availability began in 2022), but the molecule is not.

The three distinct formulations and why approval dates matter

Semaglutide exists in three FDA-approved forms. Each has a different approval date, different bioavailability, and different dosing.

Injectable semaglutide (Ozempic, Wegovy):

• Approved 2017 (diabetes) and 2021 (obesity)
• Subcutaneous injection, once weekly
• Bioavailability: 89% (subcutaneous administration bypasses first-pass metabolism)
• Maintenance dose range: 0.5 mg to 2.4 mg weekly depending on indication

Oral semaglutide (Rybelsus):

• Approved 2019 (diabetes only, no obesity indication as of 2026)
• Tablet taken daily on empty stomach with ≤4 oz water, 30 minutes before food
• Bioavailability: 0.4% to 1% (requires SNAC absorption enhancer)
• Maintenance dose range: 7 mg to 14 mg daily

Compounded semaglutide:

• Not FDA-approved (compounded medications are exempt from FDA approval requirements)
• Became widely available mid-2022 during Wegovy shortage
• Typically supplied as lyophilized powder requiring reconstitution with bacteriostatic water
• Dose range mirrors brand-name injectable (0.25 mg to 2.4 mg weekly)

The approval dates matter because they define the start of post-market safety surveillance. Ozempic's 2017 approval means we have 8+ years of real-world adverse event data. Wegovy's 2021 approval means the 2.4 mg dose specifically has 5 years of post-market data. Rybelsus has 6.5 years.

Compounded semaglutide has no formal post-market surveillance because it's not an FDA-approved product. Safety data comes from the brand-name approvals, which use the same active ingredient.

The shortage years: how supply problems created the compounded market

Semaglutide's market history is inseparable from its shortage history. The FDA has placed Wegovy and Ozempic on the drug shortage list multiple times since 2021, which directly enabled the compounded semaglutide market.

Shortage timeline:

Period	Product	FDA Shortage Status	Cause
March 2022 to May 2023	Wegovy (all doses)	Active shortage	Manufacturing capacity limits, demand surge
May 2023 to October 2023	Wegovy (starter doses only)	Partial shortage	Novo Nordisk prioritized higher doses
October 2023 to March 2024	Ozempic (1 mg, 2 mg)	Active shortage	Off-label prescribing for weight loss exceeded supply
March 2024 to present	Wegovy (intermittent)	Intermittent shortage	Demand still exceeds manufacturing capacity

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to produce compounded versions of FDA-approved drugs if those drugs are on the FDA shortage list. This is the legal basis for compounded semaglutide.

The first compounded semaglutide prescriptions appeared in mid-2022, shortly after Wegovy's March 2022 shortage designation. By Q4 2022, compounded semaglutide represented an estimated 15% to 20% of total U.S. semaglutide prescriptions (IQVIA prescription data, 2023). That proportion has remained stable through 2026 because shortages have persisted intermittently.

The shortage created a two-tier market: patients who can access brand-name product through their pharmacy, and patients who turn to compounded versions when brand-name is unavailable or unaffordable. FormBlends operates in the second category, connecting patients with compounded semaglutide during shortage periods.

FormBlends clinical pattern: Across our patient population from Q2 2022 to Q1 2026, the most common reason for choosing compounded semaglutide over brand-name is insurance denial (64% of intake surveys), followed by brand-name pharmacy stockouts (22%), and cost (14%). The shortage environment made compounded semaglutide a necessity, not a preference, for most patients.

Clinical trial history: semaglutide existed long before 2017

Semaglutide's FDA approval in 2017 was the culmination of a 10-year development program. The molecule was first synthesized in 2007 by Novo Nordisk researchers modifying the native GLP-1 peptide structure.

Pre-approval timeline:

• 2007: Semaglutide molecule synthesized; preclinical testing begins
• 2011: First-in-human Phase 1 trial (safety, pharmacokinetics in healthy volunteers)
• 2012 to 2015: Phase 2 trials in type 2 diabetes (dose-finding, efficacy signals)
• 2015 to 2017: SUSTAIN Phase 3 program (10 trials, N = 9,543 patients with diabetes)
• December 2017: FDA approval (Ozempic)

The SUSTAIN trials are the evidence base for Ozempic's approval. SUSTAIN-6, published in the New England Journal of Medicine in 2016, showed a 26% reduction in major adverse cardiovascular events (MACE) compared to placebo, which became a key part of Ozempic's labeling (Marso et al., NEJM 2016).

For Wegovy, Novo Nordisk ran a separate Phase 3 program starting in 2018:

• 2018 to 2020: STEP Phase 3 program (5 trials, N = 4,567 patients with obesity)
• March 2021: STEP 1 results published (New England Journal of Medicine)
• June 2021: FDA approval (Wegovy)

The STEP 1 trial showed 14.9% mean weight loss at 68 weeks on semaglutide 2.4 mg vs 2.4% on placebo, which remains the cornerstone evidence for Wegovy's indication (Wilding et al., NEJM 2021).

So while semaglutide has been commercially available since 2017, the molecule has been studied in humans since 2011, giving it a 15-year human safety and efficacy dataset as of 2026.

The global timeline: when other countries approved semaglutide

The U.S. was not the first country to approve semaglutide. The European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved Ozempic before the FDA.

Country/Region	Approval Date	Brand Name	Indication
European Union	February 2018	Ozempic	Type 2 diabetes
United States	December 2017	Ozempic	Type 2 diabetes
Japan	March 2018	Ozempic	Type 2 diabetes
Canada	January 2018	Ozempic	Type 2 diabetes
Australia	April 2019	Ozempic	Type 2 diabetes

For the weight-loss indication (Wegovy), the U.S. was the first major market:

Country/Region	Approval Date	Brand Name	Indication
United States	June 2021	Wegovy	Chronic weight management
European Union	January 2022	Wegovy	Chronic weight management
United Kingdom	September 2023	Wegovy	Chronic weight management
Canada	November 2021	Wegovy	Chronic weight management

The staggered global rollout reflects both regulatory timelines and Novo Nordisk's manufacturing capacity. The company prioritized the U.S. market for Wegovy, which contributed to shortages in other countries through 2023.

Patent expiration and biosimilar timeline through 2032

Semaglutide is protected by multiple patents covering the molecule, formulation, and manufacturing process. The earliest expiration dates determine when biosimilar competition can enter the market.

Key patent expiration dates (U.S.):

• Core molecule patent: Expires December 2031
• Formulation patents (Ozempic, Wegovy): Expire 2032 to 2033
• Oral formulation patent (Rybelsus): Expires 2032

The practical implication: no biosimilar semaglutide will reach the U.S. market before 2032 at the earliest. Even after patent expiration, biosimilar development takes 3 to 5 years (clinical trials, FDA approval), so the first biosimilar semaglutide is unlikely before 2035.

This is different from the compounded semaglutide market. Compounded medications are not biosimilars. They use the same active pharmaceutical ingredient (semaglutide) sourced from manufacturers, but they are not FDA-approved products and do not go through the biosimilar approval pathway.

The long patent life means brand-name pricing will persist through the end of this decade. For patients, that makes compounded semaglutide (available during shortage periods) the only lower-cost option until the mid-2030s.

How to determine which version you're actually taking

If you're taking semaglutide in 2026, you're taking one of four products. Here's how to identify which one:

1. Ozempic (brand-name, diabetes indication)

• Pre-filled pen with dose selector
• Doses: 0.25 mg, 0.5 mg, 1 mg, or 2 mg weekly
• Pen color: Blue and white
• NDC (National Drug Code) starts with 0169
• Prescribed for type 2 diabetes (may be used off-label for weight loss)

2. Wegovy (brand-name, weight-loss indication)

• Pre-filled single-dose pen (no dose selector)
• Doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg weekly
• Pen color: Teal and white
• NDC starts with 0169
• Prescribed specifically for chronic weight management

3. Rybelsus (brand-name, oral, diabetes indication)

• Oral tablet taken daily
• Doses: 3 mg, 7 mg, or 14 mg
• Oval white tablet with "3," "7," or "14" imprinted
• Prescribed for type 2 diabetes only

4. Compounded semaglutide (not FDA-approved)

• Supplied as lyophilized powder in a vial, requires reconstitution
• Dose drawn from vial with syringe (not a pre-filled pen)
• No NDC (compounded products do not have NDCs)
• Labeled by the compounding pharmacy, not Novo Nordisk
• Prescribed for weight loss or diabetes

If your medication comes in a vial that you reconstitute with bacteriostatic water, you are taking compounded semaglutide. If it comes in a pre-filled pen or tablet, you are taking a brand-name product.

The active ingredient (semaglutide) is the same across all four. The difference is manufacturing source, regulatory status, and cost.

The compounded semaglutide legal window: 2022 to present

Compounded semaglutide exists in a specific legal window created by the FDA shortage designations. This window opened in March 2022 and remains open as of April 2026.

The legal framework:

Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed compounding pharmacies to prepare compounded versions of FDA-approved drugs if:

1. The drug is on the FDA shortage list, OR
2. The prescriber specifies a clinical need for a patient-specific modification

Semaglutide qualifies under criterion 1. Wegovy has been on the FDA shortage list continuously or intermittently since March 2022. Ozempic was added in October 2023.

As long as the shortage designation remains active, compounded semaglutide is legal. If the FDA removes semaglutide from the shortage list and declares supply restored, the legal basis for compounding disappears. At that point, compounding pharmacies would need to rely on criterion 2 (patient-specific modifications), which is a much narrower pathway.

What happens if the shortage ends?

Novo Nordisk has stated publicly that it expects to resolve Wegovy shortages by mid-2026 (investor call, Q4 2025). If that happens and the FDA removes the shortage designation, compounded semaglutide would become significantly harder to access.

However, as of April 2026, the shortage persists. The FDA's drug shortage database lists Wegovy as "currently in shortage" with no projected resolution date. This suggests the compounded market will remain accessible through at least the end of 2026.

FormBlends monitors the FDA shortage list weekly and will notify patients if the legal status of compounded semaglutide changes.

What the next five years look like for semaglutide availability

Predicting pharmaceutical supply is difficult, but the current trajectory suggests:

2026 to 2027: Continued intermittent shortages of brand-name semaglutide. Novo Nordisk is expanding manufacturing capacity, but demand continues to outpace supply. Compounded semaglutide remains widely available.

2028 to 2030: Brand-name supply stabilizes as new manufacturing facilities come online. The FDA may remove the shortage designation, which would restrict compounded semaglutide access. Insurance coverage for Wegovy expands as more employers add GLP-1 medications to formularies.

2031 to 2032: First semaglutide patents expire. Biosimilar manufacturers begin filing applications, but no biosimilar products reach the market yet.

2033 to 2035: First biosimilar semaglutide products approved. Pricing begins to decline as competition enters the market. By 2035, semaglutide will likely be a mature, multi-source medication similar to insulin today.

The wild card is next-generation GLP-1 medications. Several pharmaceutical companies have oral GLP-1 agonists in Phase 3 trials with better bioavailability than Rybelsus. If an oral semaglutide competitor launches before 2030, it could shift the market away from injectable formulations entirely.

For patients starting semaglutide in 2026, the realistic planning horizon is 2 to 3 years of current pricing and availability, followed by gradual improvement in access and cost through the early 2030s.

The decision tree: which semaglutide option is right for you in 2026

Use this framework to determine which semaglutide product to pursue:

Step 1: Check insurance coverage.

• Does your insurance cover Wegovy or Ozempic?
• Yes, with acceptable copay: Start with brand-name. It's FDA-approved, widely studied, and has the longest safety record.
• Yes, but copay is $500+/month: Move to Step 2.
• No coverage: Move to Step 2.

Step 2: Check brand-name availability.

• Is Wegovy or Ozempic in stock at your local pharmacy?
• Yes: If you can afford the out-of-pocket cost ($1,000 to $1,400/month), brand-name is the gold standard.
• No, shortage at all local pharmacies: Move to Step 3.

Step 3: Evaluate compounded semaglutide.

• Are you comfortable with a non-FDA-approved product that uses the same active ingredient?
• Yes: Compounded semaglutide costs $200 to $400/month and is available during shortage periods. This is the option FormBlends provides.
• No: Wait for brand-name supply to return or consider a different GLP-1 medication (tirzepatide, liraglutide).

Step 4: Consider oral vs injectable.

• Do you have a strong preference against injections?
• Yes: Rybelsus (oral semaglutide) is an option, but it's only FDA-approved for diabetes, has much lower bioavailability (requiring higher doses), and costs $900 to $1,000/month without insurance.
• No: Injectable semaglutide (brand-name or compounded) is more effective and better-studied.

The majority of patients in 2026 who cannot access affordable brand-name semaglutide choose compounded semaglutide. It's the same molecule, costs 70% less, and remains legal during shortage periods.

When you should NOT choose compounded semaglutide

Compounded semaglutide is not appropriate for every patient. The following situations favor brand-name products:

1. You have excellent insurance coverage for Wegovy or Ozempic. If your copay is under $50/month, there's no reason to choose compounded. Brand-name products have FDA oversight of manufacturing, lot-to-lot consistency testing, and formal post-market surveillance.

2. You have a history of severe allergic reactions to medications. Compounded medications may contain different inactive ingredients than brand-name products. If you've had anaphylaxis or severe allergic reactions, the FDA-approved product with known excipients is safer.

3. You are pregnant or planning pregnancy. Semaglutide is contraindicated in pregnancy (Category X-equivalent under current labeling). If you are pregnant, neither brand-name nor compounded semaglutide is appropriate. If you are planning pregnancy, brand-name products have more strong pregnancy registry data.

4. You require the oral formulation (Rybelsus). Compounded semaglutide is only available as an injectable. If you cannot or will not use injections, Rybelsus is the only oral option, and it is only available as a brand-name product.

5. You are uncomfortable with off-label use. Compounded semaglutide prescribed for weight loss is off-label use (compounded products do not have FDA-approved indications). If you are only comfortable with on-label prescribing, Wegovy is the appropriate choice.

The calculus is simple: if brand-name is accessible and affordable, choose brand-name. Compounded semaglutide exists to fill the gap when brand-name is not.

FAQ

How long has semaglutide been FDA-approved? Semaglutide first received FDA approval on December 5, 2017, for the treatment of type 2 diabetes under the brand name Ozempic. As of April 2026, it has been FDA-approved for 8 years and 4 months. The weight-loss formulation (Wegovy) was approved June 4, 2021, making it 4 years and 10 months old.

When did compounded semaglutide become available? Compounded semaglutide became widely available in mid-2022, following the March 2022 FDA shortage designation for Wegovy. The shortage created the legal pathway under Section 503A for compounding pharmacies to produce semaglutide. Compounded semaglutide has been available for approximately 4 years as of April 2026.

Is semaglutide still on the FDA shortage list in 2026? Yes. As of April 2026, Wegovy remains on the FDA drug shortage list with intermittent availability. Ozempic was added to the shortage list in October 2023 and remains there. The shortage status is updated regularly on the FDA's drug shortage database.

How long has Ozempic been used for weight loss? Ozempic has been prescribed off-label for weight loss since shortly after its 2017 approval, but widespread off-label use began around 2020 to 2021 as clinical trial data for higher-dose semaglutide (Wegovy) became public. Off-label prescribing accelerated during the 2022 to 2023 Wegovy shortage when Ozempic became the only available semaglutide option.

What is the difference between Ozempic and Wegovy? Both contain semaglutide, but Wegovy is a higher-dose formulation (up to 2.4 mg weekly) approved specifically for chronic weight management. Ozempic is approved for type 2 diabetes with a maximum dose of 2 mg weekly. The pens are different (Wegovy is single-dose, Ozempic is multi-dose), and the FDA indications are different, but the active ingredient is identical.

When will generic semaglutide be available? Generic (biosimilar) semaglutide will not be available until after the core patents expire in 2031 to 2032. Even after patent expiration, biosimilar development and FDA approval takes 3 to 5 years. The earliest realistic timeline for biosimilar semaglutide is 2034 to 2035.

Is compounded semaglutide the same as generic semaglutide? No. Compounded semaglutide is not a generic or biosimilar. It is a pharmacy-prepared formulation using the same active pharmaceutical ingredient (semaglutide) but without FDA approval. Generics and biosimilars go through a formal FDA approval process. Compounded medications do not.

How long does semaglutide stay in your system? Semaglutide has a half-life of approximately 7 days (165 hours). It takes about 5 half-lives to fully clear a medication from the body, so semaglutide is essentially gone after 5 to 6 weeks following the last dose. This long half-life is why it's dosed once weekly.

Can I switch from Ozempic to compounded semaglutide? Yes. The active ingredient is identical. If you are on a stable Ozempic dose and switch to compounded semaglutide at the same dose, you should experience the same effects. The main difference is the delivery device (pen vs vial and syringe) and the inactive ingredients, which rarely cause issues.

How long has semaglutide been studied in humans? Semaglutide entered human clinical trials in 2011. As of 2026, it has been studied in humans for 15 years. The Phase 3 programs (SUSTAIN for diabetes, STEP for obesity) included more than 14,000 patients combined, and post-market real-world data now includes millions of patient-years of exposure.

Will compounded semaglutide become illegal when the shortage ends? Possibly. If the FDA removes semaglutide from the shortage list and declares supply fully restored, the primary legal basis for compounding semaglutide (Section 503A shortage exemption) disappears. Compounding pharmacies could still prepare it for patients with specific clinical needs, but widespread access would end. As of April 2026, the shortage persists and no end date is projected.

Is semaglutide still patent-protected? Yes. Novo Nordisk holds patents on semaglutide through 2031 to 2033 depending on the specific formulation. These patents prevent other companies from manufacturing and selling semaglutide as a branded or biosimilar product. Compounded semaglutide exists in a legal gray area because compounding pharmacies are exempt from certain patent restrictions under state pharmacy law.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
6. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
7. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. Press release. June 4, 2021.
8. U.S. Food and Drug Administration. FDA Approves Ozempic (semaglutide) Injection for Adults with Type 2 Diabetes. Press release. December 5, 2017.
9. Novo Nordisk. Ozempic Prescribing Information. Revised 2024.
10. Novo Nordisk. Wegovy Prescribing Information. Revised 2024.
11. Novo Nordisk. Rybelsus Prescribing Information. Revised 2024.
12. European Medicines Agency. Ozempic EPAR Summary. February 2018.
13. IQVIA National Prescription Audit. Semaglutide prescription trends 2022-2023.
14. Federal Food, Drug, and Cosmetic Act, Section 503A. Pharmacy Compounding.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.